Furthermore, consistency of lung cancer may be an important predictor of survival<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Dec. 8, 2022 (HealthDay News) — There is a high cure rate for screen-detected lung cancers, according to a study presented at the annual meeting of the Radiological Society of North America, held from Nov. 27 to Dec. 1 in Chicago.<\/p>\n
Claudia Henschke, Ph.D., M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues estimated 20-year lung cancer-specific survival (LCS) among 87,416 participants enrolled in a prospective, international, multicenter study of low-dose computed tomography screening for lung cancer (I-ELCAP). The analysis included 1,285 I-ELCAP participants.<\/p>\n
The researchers found that 20-year lung cancer-specific survival was 80 percent. Lung cancer-specific survival was 100 percent for participants with nonsolid consistency and part-solid consistency and 73 percent for participants with solid consistency. For clinical stage IA participants, lung cancer-specific survival was 86 percent, regardless of consistency. Lung cancer-specific survival was 92 percent for participants with pathologic stage IA lung cancer (\u00e2\u0089\u00a410 mm in average diameter).<\/p>\n
“What we present here is the 20-year follow-up on participants in our screening program that were diagnosed with lung cancer and subsequently treated,” Henschke said in a statement. “The key finding is that even after this long a time interval they are not dying of their lung cancer.”<\/p>\n
Press Release<\/a><\/p>\n